Angiogenesis and inflammation are closely related biologic processes in wound healing and the responses to vascular injury as well as in cardiovascular diseases, however, the molecular connections are poorly defined. In particular, it is yet unclear whether endogenous factors can regulate both angiogenesis and inflammation. Here, we show that the endogenous angiogenesis inhibitor, angiostatin (containing kringle domains 1-4 of plasminogen), serves an anti-inflammatory role, since the kringles 1-3 and its kringle 4 directly interact with leukocyte 1-and 2-integrins, respectively. In particular, a specific interaction between kringle 4 and M 2-integrin (Mac-1) but not LFA-1 was identified. Angiostatin thereby inhibited 1-and 2-integrin-mediated adhesion of leukocytes to extracellular matrix proteins and the endothelium as well as their transmigration through the endothelium in vitro. Moreover, angiostatin blocked the peritonitis-induced neutrophil emigration in vivo. In addition, through its interaction with Mac-1, angiostatin reduced activation of the pro-inflammatory transcription factor NF B, as well as the NF B-related expression of tissue factor, a potent initiator of haemostasis following vascular injury. Finally, angiostatin forms were generated in vivo following skin injury/inflammation and were detectable during the following entire period of wound healing peaking at the terminal phase of the healing process. Taken together, over and above inhibition of neovascularization, angiostatin was identified as an antiadhesive / antiinflammatory substance. These observations could provide the basis for new therapeutic applications of angiostatin to target chronic inflammatory processes in different pathological situations.
Introduction
The recruitment of leukocytes is an integral part of both chronic inflammatory processes or vascular remodelling and of the immediate response towards bacterial infection or tissue injury. Leukocyte recruitment requires a coordinated sequence of multistep adhesive and signalling events including selectin-mediated rolling, leukocyte activation, and integrin-mediated firm adhesion and diapedesis (1) . During firm adhesion of leukocytes to the endothelium, members of the 2-integrin family, LFA-1 ( L 2, CD11a/CD18), Mac-1 ( M 2, CD11b/CD18), and p150,95 ( X 2, CD11c/CD18), as well as 1-integrins on the leukocyte surface interact with endothelial counterligands such as ICAM-1, surface-associated fibrinogen or VCAM-1. Whereas VLA-4 ( 4 1-integrin) mediates leukocyte adhesion to fibronectin in the extracellular matrix, Mac-1 regulates leukocyte adhesion to provisional matrix substrates including fibrinogen (FBG) which becomes deposited at sites of inflammation and injury during the phase of increased vascular permeability or damage (2) (3) (4) . Ligation and activation of Mac-1 results in modulation of gene expression mediated at least in parts by the activation of the transcription factor NF-B (5-7), which has been proposed as a critical molecular bridge between oxidant stress and gene expression as a result of cell exposure to inflammatory, infectious, or other stressful stimuli (8) (9) (10) .
Angiogenesis and inflammation are closely related in biologic processes such as wound healing and response to vascular injury. Moreover, neovascularization accompanies chronic inflammatory conditions including psoriasis, rheumatoid arthritis, and granulomatous diseases; in such cases neovascularization may function to sustain inflammation, since new capillaries facilitate leukocyte entry into inflammatory lesions (11) . The crosstalk between integrins and proteolytic systems, such as matrix metalloproteinases and the fibrinolytic system, plays a central role
For personal use only. on . by guest www.bloodjournal.org From during vascular remodelling (12) . We and others have recently demonstrated the molecular convergence of adhesive forces/contacts and the plasminogen system on the surface of leukocytes, necessary for their recruitment. Both urokinase plasminogen activator and its receptor were shown to interact with 2-integrins, in particular Mac-1, to engage this multifunctional integrin for adhesion and migration (13-15).
Angiostatin, a proteolytic fragment of plasminogen, entailing either the first three or first four kringle domains (K1-3, K1-4) of plasminogen is a potent inhibitor of angiogenesis in vivo (16) (17) (18) . After urokinase-dependent conversion of plasminogen into the two-chain serine protease, plasmin serves as both the substrate and enzyme for the generation of angiostatin (19) , however several other mechanisms have been proposed for the generation of angiostatin from plasminogen (20) . Inhibition of endothelial cell proliferation and migration by angiostatin is mediated by different kringles of the molecule (21) (22) (23) . Furthermore, angiostatin interacts with the integrins 4 1 and 9 1, as well as with v 3 (24) , which has an important function during pathologic angiogenesis due to its expression on angiogenic endothelium and its function in a spatio-temporal manner (25) . Moreover, biologically active angiostatin (K1-3) can be generated by neutrophil-derived elastase (26) , and a recent report demonstrated that angiostatin interferes with neutrophil migration and thereby chemokine-induced angiogenesis (27) , whereby the underlying mechanisms remained undefined.
These diverse observations prompted us to investigate the exact role of angiostatin in leukocyte recruitment. We demonstrate here the existence of a direct interaction between angiostatin and the 2-integrin Mac-1 and have confirmed the interaction between angiostatin and 1-integrins. These interactions define the anti- and mouse ICAM-1 (3E2) as well as respective isotype-matched control antibodies, which were used for in vivo inhibition studies, were from Pharmingen (Hamburg, Germany). MnCl 2 , fibrinogen (FBG), fibronectin (FN), -aminocaproic acid (EACA) and monocyte chemoattractant protein-1 (MCP-1) were from Sigma (Munich, Germany). Vitronectin (VN) was purified from human plasma and converted into the multimeric form as previously described (28) . Vitamin D3 was from Biomol (Hamburg, Germany), transforming growth factor-ß was from R&D Systems (Boston, MA), recombinant soluble VCAM-1 was purchased from Chemicon (Hofheim, Germany).
Recombinant human angiostatin entailing kringles 1-3 of plasminogen (amino acids 97-357), with a single amino acid mutation (N308 to E308) preventing Nglycolysation, was expressed and purified from P. Pastoris (methylatropic yeast) (29, 30) . Angiostatin forms (K1-4, K1-3 and K4) were generated and purified as previously described (18, 31) . Briefly, plasminogen was purified from human plasma For personal use only. on . by guest www.bloodjournal.org From and proteolysed with 0.75 µg elastase/100 mg plasminogen for 5 h at 37°C.
Cleavage products were then isolated by affinity chromatography using lysinesepharose and subsequently separated dependent on their molecular weight using a S300-gel filtration column. In SDS-PAGE at reducing conditions K1-4, K1-3 and K4 each appeared at 42, 38 and 14 kD, respectively. The identity of the different angiostatin forms were also verified by aminoterminal protein sequencing.
Cell culture. Myelo-monocytic THP-1 cells, K562 cells and K562 cells transfected with different 2-integrin forms, as well as human umbilical vein endothelial cells (HUVEC) were cultivated as previously described (32) (33) (34) (35) . K562 cells (nontransfected, stable LFA-1-or p150.95-transfectants) were kindly provided by Dr. Y.
van Kooyk (Amsterdam, The Netherlands) K562 cells transfected with Mac-1 were kindly provided by Dr. M. Smith (Celltech, Slough, UK). Human neutrophils were isolated from peripheral blood as previously described (33) .
Cell adhesion assay. Adhesion assays were performed as previously described (33) (34) (35) . As shown in Fig. 1 , adhesion assays of THP-1 cells or neutrophils to immobilized FBG, FN, VN, ICAM-1 or VCAM-1 (each 10 µg/mL), or to BSA as control were performed, both in the absence or presence of inhibitory antibodies or angiostatin forms in the soluble phase. Moreover, adhesion of THP-1 cells or neutrophils to immobilized angiostatin forms (K1-4, K1-3 and K4) (400 nM) was carried out as shown in Fig. 2 . Briefly, microtiter plates were coated with the respective substrates in bicarbonate buffer, pH 9.6 and blocked with 3% BSA-solution. Isolated human neutrophils, or THP-1 cells, which had been differentiated for 24 h in the presence of vitamin D3 (100 nM) and transforming growth factor-(2 ng/mL) were washed in serum-free RPMI medium and plated onto the precoated wells (10 5 /well) at 37°C for Transendothelial migration. Transendothelial migration was performed as previously described (36) . Briefly, transmigration assays were performed using 6.5 mm transwell filters with a 5 µm pore size (Costar, Bodenheim, Germany). After inserts were coated with gelatine (Sigma), HUVEC were seeded on transwell filters 2 days prior to the assay and grown without medium in the lower compartment for 48 h in a humidified atmosphere (37°C, 5% CO 2 ). At the beginning of the transmigration assay 600 µL migration assay medium (serum-free RPMI in the absence or presence of 50 ng/mL MCP-1) was added to the lower compartment of the Transwell system. . Following incubation for 2h at 22°C in each case, peroxidase-coupled streptavidin was added, followed by addition of the substrate ABTS, and binding was quantitated at 405 nm. Nonspecific binding to BSA-coated wells was used as blank and was subtracted to calculate specific binding.
Generation of cutaneous wounds and detection of angiostatin. Mice were anesthetized using 13 µl of 2.5% avertin per gram body weight. Two round cutaneous wounds were generated at both sides of the lower dorsal trunk after shaving the hair and disinfecting the skin with Softasept N (Braun Melsungen AG, Melsungen, Germany). The area of circular skin removed was 8 mm in diameter.
Curved scissors and surgical techniques were used. The wounds were well separated by more than 1 cm skin. This protocol was approved by the veterinarians of the animal facilities of the University of Heidelberg and the Govermental Office
Karlsruhe (experimental protocols 35-9185.81-2 and 35-9185.81/G-37/03).
At days 0, 1, 3, 7 and 12 after generation wounds were extracted. For the preparation of total wound extract wounds were homogenized using a pestle and liquid nitrogen and were then lysed in a buffer containing 50 mM Tris-HCL, pH 8.0, 150 mM NaCl, 0.02% Sodium azide, 1% Triton X-100, 2mM Benzamidin, 20 µg/ml soybean inhibitor, 1 mM leupeptin, 1 µg/ml aprotinin, 0.5 mM PMSF. After centrifugation (4000 rpm, 2 min., 4°C), lysates were cleared from insoluble material, The membranes were blocked with Tris-buffered saline supplemented with 0.1% Tween-20 (wash buffer) and 2% low fat milk powder and incubated with mAb TF9-6B4 against tissue factor or rabbit anti-angiostatin (Acris, Hiddenhausen, Germany) overnight at 4°C, diluted 1:500 in wash buffer containing 2.5% BSA. Following incubation with the appropriate peroxidase-conjugated secondary antibody (DAKO), blots were developed using an ECL-based system (Amersham).
Electrophoretic mobility shift assay (EMSA). Nuclear proteins were harvested as described elsewhere (39, 40) and assayed for transcription factor binding activity using the NF B consensus sequence 5-GTTGAGGGGACTTTCCCAGGC-3.
Specificity of binding was ascertained by competition with a 160-fold molar excess of unlabeled consensus oligonucleotides and by supershift experiments (39, 40) .
In vivo peritonitis model. Thioglycollate-induced peritonitis in mice was performed as previously described (34, 35, 37) . For inhibition studies, 30 min prior to the injection of thioglycollate, the following compounds were administered intraperitoneally: Various concentrations of K1-4, K1-3, K4, mAb against mouse Mac-1, against mouse LFA-1 or against mouse ICAM-1 in PBS (each mAb 100 µg). Control mice were treated with the same volume of PBS or the respective isotype-matched control antibody (100 µg). Each compound was administered in a total volume of 0.4 ml. In order to evaluate neutrophil recruitment, mice were sacrificed at 4h following injection of thioglycollate. Thereafter, the peritoneal lavage was collected and the number of emigrated neutrophils was quantitated as previously described (34, 35, 37) .
Statistical analysis. Data were compared using the Student`s t test and ANOVA as appropriate; P values of < 0.05 were regarded as significant. (Fig. 1) . Strikingly isolated K4 inhibited Mac-1-dependent adhesion comparable to K1-4, whereas K1-3 exhibited no significant inhibitory function (Fig. 1B and C). In addition, VLA-4-dependent THP-1 cell adhesion to FN and VCAM-1 was also blocked by K1-4, somehow to a less extent. However, in this case the isolated K4 was not inhibitory, whereas K1-3 and K1-4 blocked adhesion to a similar degree ( Fig. 1D and 1E) . Coincubation of K1-3 with K4 did not enhance the inhibitory function of K1-3 and of K4 on VLA-4-dependent and Mac-1-dependent adhesion, respectively (Fig. 1F) . Together, K1-4 prevents both VLA-4-and Mac-1-dependent neutrophil and THP-1 adhesion, whereby K1-3 primarily interfered with VLA-4-and K4 with Mac-1-dependent adhesive events.
These observations indicated a direct interaction of different kringles in the angiostatin molecule with leukocyte integrins. Therefore, we studied whether For personal use only. on . by guest www.bloodjournal.org From 13 leukocytes could directly bind to immobilized angiostatin forms. THP-1 cells not only adhered to K1-4, but adhesion to K1-4 was inhibited by a blocking monoclonal antibody (mAb) against 2-integrins and to a lower extent by a blocking mAb against 1-integrin ( Fig. 2A) . Moreover, myelomonocytic cell adhesion to immobilized K1-4 was inhibited by a blocking mAb against Mac-1, whereas a blocking mAb against LFA-1 or p150,95 did not significantly affect cell adhesion (Fig. 2a) . To further investigate the participation of K1-3 and K4 in these interactions, we studied adhesion of THP-1 cells to immobilized fragments of angiostatin. Adhesion to immobilized K1-3 was abolished by a blocking mAb against 1-and 4-integrin, whereas anti-2-integrin antibodies were ineffective. In contrast, adhesion to immobilized K4 was only reduced by a blocking mAb against 2-integrin and mAb against Mac-1, whereas blocking mAb against 1-integrins were ineffective ( Fig. 2B and 2C). Furthermore, adhesion of THP-1 cells to immobilized K1-4, K1-3 and K4 was totally abolished by -Aminocaproic acid (EACA), indicating that lysine-binding sites in angiostatin are required for interaction with integrins ( Fig. 2A-C) . Similar results were also observed when adhesion of peripheral blood neutrophils was tested (not shown). Moreover, these data were corroborated by testing the adhesion of non- 
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Since the previous observations implicated that K1-4 and the portion thereof K4 could directly bind to the 2-integrin Mac-1, these angiostatin forms were tested for their interference with the interaction of other Mac-1 ligands. In a purified system, K1-4 and K4 but not K1-3 inhibited the binding of FBG and ICAM-1 to immobilized Mac-1 ( Fig. 3A and B) , whereas binding of ICAM-1 to LFA-1 was not affected (data not shown). A specific and saturable binding of K1-4 (but not K1-3) to immobilized Mac-1 (but not LFA-1) was also observed (data not shown). We then tested whether angiostatin binds to the major ligand-binding I domain of Mac-1, and a direct saturable binding of biotinylated I-domain to immobilized K1-4 or K4 (but not to K1-3) was observed (Fig. 3C ). These data indicate that K1-4 and particularly K4 directly significantly blocked neutrophil adhesion to the endothelium, and upon coincubation their inhibitory effect was comparable to the anti-adhesive function of K1-4 (Fig. 4A) .
The effect of K1-4, K1-3 and K4 on neutrophil adhesion to HUVEC was also dosedependent (Fig. 4B) . The IC50 of K1-4, K1-3 and K4 were 150 nM, 500 nM and 400 nM, respectively.
In contrast, neutrophil transendothelial migration was predominantly mediated by Mac-1 while mAb against 1-integrin exhibited no inhibitory activity. Consistent with the previous observation that K4 predominantly interacts with Mac-1 and K1-3 with 1integrin, monocyte chemoattractant protein-1 (MCP-1)-stimulated neutrophil transmigration through endothelial cells was prevented in the presence of K1-4 or K4 whereas a weak (about 25-30%) inhibition of neutrophil transmigration was provided only by the highest concentration of K1-3 (1000 nM) ( Fig. 4C and D) . Together, angiostatin can block neutrophil adhesion to and transmigration through the endothelium in vitro.
Inhibition of neutrophil recruitment by angiostatin in acute peritonitis in mice.
To test whether angiostatin interferes with leukocyte recruitment in vivo, we studied its role in a mouse model of acute inflammation. Peritonitis was induced by thioglycollate injection, and after 4 h there was the expected increase in the total leukocyte count in the peritoneum, mostly attributable to emigrated neutrophils: The portion of neutrophils among all leukocytes after 4 h was 50-60 % (34, 35, 37) . The use of blocking antibodies against LFA-1, Mac-1 or ICAM-1 30 min prior to the induction of peritonitis resulted in a 60-75% inhibition of neutrophil extravasation into the inflamed peritoneum at 4 h following thioglycollate injection (Fig. 5A ) (data with antibody against ICAM-1 not shown). Also, application of recombinant angiostatin (100 µg) also resulted in a significant inhibition of neutrophil extravasation ( Figure   5A ). We then compared the effects of 40 or 100 µg (2 or 5 mg/kg, respectively) of each of K1-4, K1-3 and K4 to block neutrophil recruitment. In mice that were For personal use only. on April 15, 2017. by guest www.bloodjournal.org From pretreated with these forms of angiostatin, K1-4 provided the maximal inhibition (>60%) with the higher dose administered (Fig. 5B) , while also significant inhibition of neutrophil recruitment (about 40-50 %) was observed after pre-treatment of mice with the lower dose of K1-4 or the higher dose of isolated K4, whereas K1-3 exhibited no significant inhibition at both doses tested (Fig. 5B) .
Inhibition of the activity of the transcription factor nuclear factor-B (NF-B) in leukocytes by angiostatin.
The transcription factor NF-B has been proposed as a critical molecular bridge between inflammatory, infectious, or other stressful stimuli and gene expression (8- (Fig. 6B) . Again the inhibitory effect of K1-4 on tissue factor expression was prevented in the presence of mAb against Mac-1, which was shown before ( 
Generation of angiostatin during inflammation
We then went on to investigate whether angiostatin can be generated physiologically during inflammation. We therefore performed western blot analysis to detect angiostatin forms in wound homogenisates from mice. In the normal mouse cutaneous tissue only plasminogen but no angiostatin forms were detectable. In contrast, angiostatin forms were detected during wound healing (Fig. 7A ). In this model wound healing is complete after 8-9 days. In order to study the kinetics of angiostatin generation in wound healing, wounds were extracted at day 0, 1, 3, 7 and 10 after generation of the wounds. Interestingly, plasminogen and angiostatin forms were expressed even at Day 1 and Day 3 after generation of the wounds; ie. at the initial phase of wound healing. The expression of angiostatin forms peaked at the last phase of wound healing (Day 7 after generation of the wounds) and almost disappeared after wound healing was complete at day 10. (Fig. 7B) . Furthermore, we detected angiostatin forms in the fluid from human wounds (data not shown). Thus, angiostatin can be generated during inflammation and wound healing where it is like to exert its anti-inflammatory and anti-angiogenic effects. 
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Thus, the anti-inflammatory action of angiostatin extends also to events that are downstream to integrin-dependent adhesion, such as blockade of NF B activity.
Moreover, since tissue factor is a major initiator of haemostasis after vascular injury, inhibition of its expression by angiostatin indicates that angiostatin serves a further yet unrecognized function as a local regulator of the coagulatory activity in the tissue. Strikingly, tissue factor was recently reported to block the angiostatin-mediated inhibition of endothelial cell proliferation (44) . This observation together with the present finding that angiostatin inhibits tissue factor expression may lead to the intriguing conclusion that downregulation of tissue factor expression by angiostatin provides a feedback mechanism that prolongs the local activity of angiostatin in the tissue. Further studies are needed to address this issue in detail.
Our findings revealed that K4 of angiostatin entails the central region of the polypeptide that serves as integrin ligand with anti-adhesive activity. This is in accordance with previous studies demonstrating that K4, which has only marginal anti-proliferative activity on endothelial cells, is the most potent fragment in inhibiting endothelial cell migration with an IC50 similar to values presented here. In contrast, kringle 1-3, which is equivalent to angiostatin in inhibiting endothelial cell proliferation, manifests only a modest anti-migratory effect (21) (22) (23) . Further studies are needed to characterize the functional differences of these kringle fragments despite their high conformational uniformity and nearly 50 % sequence identity.
The present study extends previous findings that angiostatin specifically interacts with 1-integrins and v 3-integrin on endothelial cells in an RGDdependent manner (24) , thereby interfering with the interaction between plasmin and v 3-integrin and inhibiting plasmin-induced endothelial cell migration (45) . In accordance with the previous works, we find here that binding of angiostatin to Mac-1 or 4 1-integrin was also blocked by EACA, a lysine analogue. The respective Angiostatin might thereby be a crucial player linking inflammation and angiogenesis under both physiologic conditions such as wound healing, and pathologic situation such as in rheumatoid arthritis, psoriasis, diabetic retinopathy or atherosclerosis. Chemokines have potent angiogenic activities (27) and a previous report indicated that angiostatin inhibits inflammation-related angiogenesis independent of the inducing agent (i.e. CXCR2 agonists, formyl-Met-Leu-Phe, or LPS), suggesting that it interferes with a downstream pathway common to these stimulants (27) , and we here provide evidence for a likely mechanism underlying this phenomenon. Finally, in a very recent study administration of angiostatin reduced lesion progression and the infiltration of macrophages into atheromas (52), which might be not only an indirect consequence of reduced plaque neovascularization but also due to a direct effect of angiostatin on inflammatory cells according to our present data. In essence, by affecting leukocytes and endothelial cells, angiostatin plays a crucial role at the interface between inflammation and angiogenesis and our data are meant to stimulate our thinking about novel therapeutic applications for this endogenous molecule. 
